Residual antimalarials in malaria patients from Tanzania - Implications on drug efficacy assessment and spread of parasite resistance

PLoS ONE

Volumn 4, Issue 12, 2009, Pages

  Hodel, Eva Maria ^a   Kabanywanyi, Abdunoor Mulokozi ^b   Malila, Aggrey ^b   Zanolari, Boris ^c   Mercier, Thomas ^c   Beck, Hans Peter ^a   Buclin, Thierry ^c   Olliaro, Piero ^d   Decosterd, Laurent Arthur ^c   Genton, Blaise ^a,c  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b IFAKARA HEALTH INSTITUTE   (Tanzania)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; BENFLUMETOL; CHLOROQUINE; DEBUTYLBENFLUMETOL; DRUG METABOLITE; FANSIDAR; PYRIMETHAMINE; QUININE; SULFADOXINE; UNCLASSIFIED DRUG; DRUG RESIDUE;

ADOLESCENT; ADULT; AGED; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG INTERMITTENT THERAPY; DRUG MONITORING; DRUG SAFETY; DRUG USE; FEMALE; HEALTH CARE AVAILABILITY; HEALTH CARE FACILITY; HEALTH CARE POLICY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MASS SPECTROMETRY; PREGNANCY; RURAL AREA; SELF REPORT; TANZANIA; TREATMENT OUTCOME; ANIMAL; BLOOD; DRUG EFFECT; DRUG RESISTANCE; GEOGRAPHY; INFANT; MALARIA; MIDDLE AGED; PARASITE; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; DRUG RESIDUES; DRUG RESISTANCE; FEMALE; GEOGRAPHY; HUMANS; INFANT; MALARIA; MALE; MIDDLE AGED; PARASITES; SULFADOXINE; TANZANIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77949517865     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008184     Document Type: Article

References (39)

1. World Health Organization (2003) Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Available from http://apps.who.int/malaria/docs/ProtocolWHO.pdf.
2. Nwanyanwu O, Redd S, Ziba C, Luby S, Mount D, et al. Validity of mother's history regarding antimalarial drug use in Malawian children under five years old. Trans R Soc Trop Med Hyg 90: 66-68.
3. Mahomva A, Peterson D, Rakata L (1996) Does an antimalarial drug history mean anything? Cent Afr J Med 42: 345-346.
4. Wichmann O, Eggelte T, Gellert S, Osman M, Mylius F, et al. (2007) High residual chloroquine blood levels in African children with severe malaria seeking healthcare. Trans R Soc Trop Med Hyg 101: 637-642.
5. Quashie N, Akanmori B, Goka B, Ofori-Adjei D, Kurtzhals J (2005) Pretreatment blood concentrations of chloroquine in patients with malaria infection: relation to response to treatment. J Trop Pediatr 51: 149-153.
6. Evans J, May J, Tominski D, Eggelte T, Marks F, et al. (2005) Pre-treatment with chloroquine and parasite chloroquine resistance in Ghanaian children with severe malaria. QJM 98: 789-796.
7. Ehrhardt S, Mockenhaupt F, Eggelte T, Agana-Nsiire P, Stollberg K, et al. Chloroquine blood concentrations and molecular markers of chloroquine-resistant Plasmodium falciparum in febrile children in northern Ghana. Trans R Soc Trop Med Hyg 97: 697-701.
8. Ofori-Adjei D, Commey J, Adjepon-Yamoah K (1984) Serum chloroquine levels in children before treatment for malaria. Lancet 1: 1246.
9. Talisuna A, Langi P, Bakyaita N, Egwang T, Mutabingwa T, et al. Intensity of malaria transmission, antimalarial-drug use and resistance in Uganda: what is the relationship between these three factors? Trans R Soc Trop Med Hyg 96: 310-317.
10. Verhoef H, Hodgins E, Eggelte T, Carter J, Lema O, et al. (1999) Anti-malarial drug use among preschool children in an area of seasonal malaria transmission in Kenya. Am J Trop Med Hyg 61: 770-775.
11. Schwick P, Eggelte T, Hess F, Tueumuna T, Payne D, et al. (1998) Sensitive ELISA dipstick test for the detection of chloroquine in urine under field conditions. Trop Med Int Health 3: 828-832.
12. Mockenhaupt F, May J, Bergqvist Y, Ademowo O, Olumese P, et al. (2000) Concentrations of chloroquine and malaria parasites in blood in Nigerian children. Antimicrob Agents Chemother 44: 835-839.
13. Hellgren U, Ericsson O, Kihamia C, Rombo L (1994) Malaria parasites and chloroquine concentrations in Tanzanian schoolchildren. Trop Med Parasitol 45: 293-297.
14. Tippawangkosol P, Na-Bangchang K, Ubalee R, Congpuong K, Sirichaisinthop J, et al. (1999) Investigations of incidence of pretreatment, drug sensitivity in vitro, and plasma levels of pyrimethamine in patients with multidrug resistant falciparum malaria following the three combination regimens of artemether/pyrimethamine. Southeast Asian J Trop Med Public Health 30: 220-224.
15. Nsimba S, Rimoy G (2005) Self-medication with chloroquine in a rural district of Tanzania: a therapeutic challenge for any future malaria treatment policy change in the country. J Clin Pharm Ther 30: 515-519.
16. Pfeiffer K, Some F, Muller O, Sie A, Kouyaté B, et al. (2008) Clinical diagnosis of malaria and the risk of chloroquine self-medication in rural health centres in Burkina Faso. Trop Med Int Health 13: 418-426.
17. Rombo L, Kihamia C, Mahikwano L, Ericsson O, Sjoqvist F (1986) Concentrations of chloroquine and desethylchloroquine in capillary blood dried on filter paper during and after treatment of Tanzanian children infected with Plasmodium falciparum. Trop Med Parasitol 37: 237-240.
18. Hodel E, Zanolari B, Mercier T, Biollaz J, Keiser J, et al. (2009) A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 877: 867-886.
19. Hetzel M, Alba S, Fankhauser M, Mayumana I, Lengeler C, et al. (2008) Malaria risk and access to prevention and treatment in the paddies of the Kilombero Valley, Tanzania. Malar J 7: 7.
20. Hetzel M, Iteba N, Makemba A, Mshana C, Lengeler C, et al. (2007) Understanding and improving access to prompt and effective malaria treatment and care in rural Tanzania: the ACCESS Programme. Malar J 6: 83.
21. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM) (2001) Guidance for Industry: Bioanalytical Method Validation. Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
22. White NJ, van Vugt M, Ezzet F (1999) Clinical pharmacokinetics and pharmacodynamics of artemether-lumefanrine. Clin Pharmacokinet 37: 105-25.
23. Jackson P, Tucker G, Woods H (1991) Backtracking booze with Bayes-the retrospective interpretation of blood alcohol data. Br J Clin Pharmacol 31: 55-63.
24. Price R, Uhlemann A, van Vugt M, Brockman A, Hutagalung R, et al. (2006) Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 42: 1570-1577.
25. Rahman M, Dondorp A, Day N, Lindegardh N, Imwong M, et al. (2008) Adherence and efficacy of supervised versus non-supervised treatment with artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial. Trans R Soc Trop Med Hyg 102: 861-867.
26. Newton P, van Vugt M, Teja-Isavadharm P, Siriyanonda D, Rasameesoroj M, et al. (2002) Comparison of oral artesunate and dihydroartemisinin antimalarial bioavailabilities in acute falciparum malaria. Antimicrob Agents Chemother 46: 1125-1127.
27. White N, Looareesuwan S, Warrell D, Warrell M, Bunnag D, et al. (1982) Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. Am J Med 73: 564-572.
28. Babalola C, Bolaji O, Ogunbona F, Sowunmi A, Walker O (1998) Pharmacokinetics of quinine in African patients with acute falciparum malaria. Pharm World Sci 20: 118-122.
29. White N (1997) Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 41: 1413-1422.
30. White N, Pongtavornpinyo W (2003) The de novo selection of drug-resistant malaria parasites. Proc Biol Sci 270: 545-554.
31. Stepniewska K, White N (2008) Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother 52: 1589-1596.
32. Mansor S, Navaratnam V, Mohamad M, Hussein S, Kumar A, et al. (1989) Single dose kinetic study of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef) in healthy male volunteers. Br J Clin Pharmacol 27: 381-386.
33. Obua C, Hellgren U, Ntale M, Gustafsson L, Ogwal-Okeng J, et al. (2008) Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. Br J Clin Pharmacol 65: 493-501.
34. Green M, van Eijk A, van Ter Kuile F, Ayisi J, Parise M, et al. (2007) Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya. J Infect Dis 196: 1403-1408.
35. Trenque T, Simon N, Villena I, Chemla C, Quereux C, et al. (2004) Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis. Br J Clin Pharmacol 57: 735-741.
36. Barnes K, Little F, Smith P, Evans A, Watkins W, et al. (2006) Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther 80: 582-596.
37. Edstein M (1987) Pharmacokinetics of sulfadoxine and pyrimethamine after Fansidar administration in man. Chemotherapy 33: 229-233.
38. Corvaisier S, Charpiat B, Mounier C, Wallon M, Leboucher G, et al. (2004) Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis. Antimicrob Agents Chemother 48: 3794-3800.
39. Obua C, Ntale M, Lundblad M, Mahindi M, Gustafsson L, et al. (2006) Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda. Afr Health Sci 6: 86-92.